Drug Pipeline

Olomorasib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
3
Recruiting
2
Phase 3
3
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-04 NCT06890598
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With…		 Trial sites expanded: 354 -> 361 locations
2026-05-20 NCT07439250
A Study of Olomorasib (LY3537982) in Healthy Participants		 Trial completed
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-10 NCT07639242 Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or… Phase 2 Not Yet Recruiting
Active Studies by Phase
Phase 3
2
Phase 2
1
Phase 1/2
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06119581 A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without… Carcinoma, Non-Small-Cell Lung Recruiting
NCT06890598 Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With… Carcinoma, Non-Small-Cell Lung Recruiting
Phase 2
NCT07639242 Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or… Lung Cancer Not Yet Recruiting
Phase 1/2
NCT07227025 A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic… Carcinoma, Non-Small-Cell Lung Recruiting
NCT04956640 Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) Carcinoma, Non-Small-Cell Lung Active, Not Recruiting
Sponsors Running Olomorasib Trials
Eli Lilly and Company (3) Janssen Research & Development, LLC (1) UNC Lineberger Comprehensive Cancer Center (1)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (5) Colorectal Cancer (1) Pancreatic Cancer (1) Ovarian Cancer (1) Lung Cancer (1)
Get alerts when Olomorasib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free